The quest for effective therapies in dopaminergic disorders has intensified. Cabergoline emerges as a noteworthy player. This ergot-derived dopamine agonist offers promise in addressing disorders such as Parkinson’s disease and prolactinomas. The drug targets dopamine receptors, modulating neurotransmission. This discussion highlights cabergoline’s role in treating... Continue reading
